🔍

SANOFI - Sanofi India

📊 NSE: SANOFI 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/14/2025 12:48

📢 Recent Corporate Announcements

Sanofi India FY25 PBT Rises 1% Amid Transformation; Proposes INR 123 Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Mar 2026, 03:50 PM

Sanofi India reported a 1% increase in Profit Before Tax for FY2025, navigating a significant business transformation including the demerger of its consumer health business. Domestic sales remained flat at INR 1,511 crores, though the core diabetes franchise showed strong momentum with 6% annual growth and 11% growth in Q4. The company achieved a 17% reduction in operating expenses through efficiency measures and partnership models. A total dividend of INR 123 per share has been proposed, representing a 5% increase over the previous year.

Diabetes franchise grew 6% in FY25, with Q4 growth accelerating to 11%
Lantus maintained market leadership with a 31% share in the basal insulin segment
Operating expenses were reduced by 17% through business model modernization
Proposed total dividend of INR 123 per share for the year, up 5% from 2024
Domestic net sales stood at INR 1,511 crores, while exports declined due to the Ankleshwar site divestment

💡 Investors should monitor the stabilization of the new partnership model and the growth of the insulin portfolio. The significant reduction in operating costs and consistent dividend payout remain key positives for long-term holders.

Sanofi India Releases Video Recording of Q4 and FY2025 Earnings Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Feb 2026, 04:06 PM

Sanofi India Limited has informed the exchanges that the video recording of its Investor/Analysts Call held on February 26, 2026, is now available. The call focused on the company's financial performance for the quarter and the full year ended December 31, 2025. This disclosure is part of the company's compliance with SEBI Listing Obligations and Disclosure Requirements. Investors can access the recording on the company's official website to review management's commentary on the annual results.

Video recording of the Investor Call held on February 26, 2026, has been uploaded.
The call discussed financial results for the quarter and year ended December 31, 2025.
Filing made in accordance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Recording is accessible via the 'Analyst / Investor Meet' section of the company's website.

💡 Investors should review the recording to gain deeper insights into management's strategy and outlook for the upcoming fiscal year. No immediate trading action is required based solely on this procedural filing.

Sanofi India FY25 Net Sales Up 1%, Proposes ₹123 Dividend Amid Business Transformation

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 26 Feb 2026, 03:16 PM

Sanofi India Limited (SIL) has completed a pivotal business transformation in 2025, shifting focus toward its Diabetes franchise and a partnership model for legacy brands. While FY25 total income fell 9% to ₹18,571 million due to lower other operating income, net sales grew 1% to ₹15,115 million and Profit Before Tax (PBT) rose 1% to ₹4,720 million. The company achieved a significant 17% reduction in operating expenses through structural efficiencies. A dividend of ₹123 per share has been proposed, marking a 5% increase from the previous year.

FY25 Net Sales reached ₹15,115 million, a 1% increase, while PBT before exceptional items rose 1% to ₹4,720 million.
Operating expenses were slashed by 17% in FY25 to ₹4,489 million, driven by employee cost and OPEX efficiencies.
The Diabetes franchise maintained a 31% market share with a 6% volume acceleration and double-digit growth in Toujeo.
Proposed dividend for 2025 is ₹123 per share, up from ₹117 in 2024, representing an 87% payout ratio.
Q4 2025 performance was softer with PBT declining 27% to ₹830 million compared to Q4 2024.

💡 Investors should view the successful cost optimization and the 5% dividend hike as signs of financial discipline during a major strategic pivot. Monitor the scaling of the new partnership model for legacy brands and the growth of the high-margin insulin portfolio in upcoming quarters.

Sanofi India FY25 Profit at ₹3,267M; Total Dividend of ₹123 Per Share Declared

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 25 Feb 2026, 07:08 PM

Sanofi India reported a total revenue of ₹18,374 million for FY25, down from ₹20,132 million in FY24. Despite the revenue decline, Profit Before Tax from continuing operations improved slightly to ₹4,447 million compared to ₹4,314 million in the previous year. The company has recommended a final dividend of ₹48 per share, which, combined with the interim dividend, brings the total FY25 payout to ₹123 per share. Additionally, the board announced key leadership changes, including the appointment of Ms. Sudipta Chakraborty as Whole-time Director.

Total dividend for FY25 stands at ₹123 per equity share (Final ₹48 + Interim ₹75)
FY25 Revenue from Operations decreased to ₹18,374 million from ₹20,132 million in FY24
Profit Before Tax from continuing operations rose to ₹4,447 million versus ₹4,314 million YoY
Ms. Sudipta Chakraborty appointed as Whole-time Director for a 3-year term effective March 1, 2026
Mrs. Rajani Kesari appointed as Independent Director for a 5-year term effective April 1, 2026

💡 Investors should note the strong dividend yield provided by the ₹123 total payout. While revenue from continuing operations has seen some pressure, the improvement in PBT and the induction of experienced leadership in legal and finance roles are positive signs for governance and strategy.

Sanofi India FY25 Profit at ₹3,267M; Total Dividend Recommended at ₹123 Per Share

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 25 Feb 2026, 07:03 PM

Sanofi India reported a profit of ₹3,267 million for the financial year ended December 31, 2025, compared to ₹4,135 million in FY24, which included gains from discontinued operations. Revenue from operations for FY25 declined to ₹18,374 million from ₹20,132 million in the previous year. The Board has recommended a final dividend of ₹48 per share, which, combined with the interim dividend, brings the total payout for the year to ₹123 per share. Significant management changes were also announced, including the appointment of a new Whole-time Director and an Independent Director.

Total dividend for FY25 stands at ₹123 per share, including a newly recommended final dividend of ₹48.
Revenue from operations for FY25 decreased by 8.7% to ₹18,374 million from ₹20,132 million in FY24.
Profit from continuing operations for FY25 saw a slight increase to ₹3,267 million from ₹3,137 million in FY24.
Ms. Sudipta Chakraborty appointed as Whole-time Director for 3 years effective March 1, 2026.
Mrs. Rajani Kesari appointed as Independent Director for a 5-year term starting April 1, 2026.

💡 Investors should value the consistent high dividend payout which offers a strong yield. While revenue has dipped, the stability in profits from continuing operations and the induction of experienced leadership in legal and finance roles are positive for long-term governance.

Sanofi India Declares ₹123 Total Dividend for FY25; FY25 Continuing Profit Rises to ₹3,267 Million

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 25 Feb 2026, 06:49 PM

Sanofi India has recommended a final dividend of ₹48 per share, bringing the total dividend for FY25 to a substantial ₹123 per share. The company reported a 4.1% growth in profit from continuing operations to ₹3,267 million for the full year 2025, despite a decline in annual revenue to ₹18,374 million. Significant leadership changes were announced, including the appointment of Mrs. Rajani Kesari as an Independent Director and Ms. Sudipta Chakraborty as a Whole-time Director. While Q4 revenue saw a year-on-year decline, the high dividend payout remains a key highlight for shareholders.

Total dividend of ₹123 per share for FY25, including a final dividend of ₹48 and an interim of ₹75.
Profit from continuing operations grew to ₹3,267 million in FY25 from ₹3,137 million in FY24.
Annual revenue from operations for FY25 stood at ₹18,374 million, compared to ₹20,132 million in FY24.
Appointment of Mrs. Rajani Kesari (former CFO of Nayara Energy) as Independent Director for a 5-year term.
Q4 FY25 profit after tax stood at ₹617 million, down from ₹913 million in the same quarter last year.

💡 Investors should view the high dividend payout as a sign of strong cash flow and commitment to shareholder returns. While revenue growth is currently soft, the steady profit from continuing operations and professional leadership additions support a long-term hold strategy.

Sanofi India Recommends Rs 48 Final Dividend; Total FY25 Dividend Reaches Rs 123 Per Share

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 25 Feb 2026, 06:40 PM

Sanofi India has recommended a final dividend of Rs 48 per equity share for the financial year ended December 31, 2025. When combined with the interim dividend of Rs 75 declared in October 2025, the total dividend for the year stands at Rs 123 per share. Financially, the company reported a profit from continuing operations of Rs 3,267 million for FY25, up from Rs 3,137 million in FY24, despite a decline in total revenue. The board also approved significant leadership changes, including the appointment of a new Whole-time Director and an Independent Director.

Recommended a final dividend of Rs 48 per share, bringing the total FY25 payout to Rs 123 per share
Profit from continuing operations increased to Rs 3,267 million in FY25 from Rs 3,137 million in FY24
Annual revenue from operations declined to Rs 18,374 million compared to Rs 20,132 million in the previous year
Appointed Ms. Sudipta Chakraborty as Whole-time Director for a 3-year term effective March 1, 2026
Mrs. Rajani Kesari appointed as an Independent Director for a 5-year term starting April 1, 2026

💡 Investors should benefit from the substantial dividend payout which reflects strong cash reserves. While the revenue decline needs monitoring, the growth in profit from continuing operations and high yield make it attractive for income-seeking portfolios.

Sanofi India FY25 Net Profit at ₹3,267 Mn; Total Dividend Declared at ₹123 Per Share

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 25 Feb 2026, 06:36 PM

Sanofi India reported a total net profit of ₹3,267 million for the financial year ended December 31, 2025, a decrease from ₹4,135 million in FY24 which included discontinued operations. Revenue from continuing operations for the full year stood at ₹18,374 million, down from ₹20,132 million in the previous year. The Board has recommended a final dividend of ₹48 per share, which, combined with the interim dividend, brings the total payout to ₹123 per share for 2025. Key management changes were also announced, including the appointment of Ms. Sudipta Chakraborty as a Whole-time Director effective March 2026.

Recommended a final dividend of ₹48 per share, resulting in a total annual dividend of ₹123 per share.
FY25 Revenue from continuing operations declined to ₹18,374 million from ₹20,132 million in FY24.
Profit before tax from continuing operations for FY25 rose slightly to ₹4,447 million versus ₹4,314 million in FY24.
Total Net Profit for FY25 was ₹3,267 million, compared to ₹4,135 million in FY24 which included ₹998 million from discontinued operations.
Appointed Ms. Sudipta Chakraborty as Whole-time Director and Mrs. Rajani Kesari as Independent Director.

💡 Investors should note the high dividend payout which remains a key attraction for the stock despite the decline in headline revenue. Monitor the impact of the management transition and the performance of the core continuing operations in upcoming quarters.

Sanofi India Receives Tax Demand Order of ₹2.37 Crore from Tamil Nadu Tax Authorities

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 20 Feb 2026, 12:09 PM

Sanofi India Limited has received a tax demand order from the Commercial Tax Officer, Tiruvallur, Tamil Nadu, for the financial year 2021-22. The total demand amounts to INR 2.37 crore, which includes a base tax of INR 1.34 crore, interest of INR 0.89 crore, and a penalty of INR 0.13 crore. The dispute centers on the eligibility of Input Tax Credit (ITC) from FY 2020-21 that was claimed in FY 2021-22. The company intends to contest this order by filing an appeal before the Appellate Authorities.

Total tax demand of INR 2,37,02,854 issued by the Commercial Tax Officer, Tiruvallur.
Demand breakdown includes tax of INR 1.34 crore, interest of INR 89.32 lakh, and penalty of INR 13.42 lakh.
The order relates to disputed Input Tax Credit (ITC) reconciliations for FY 2021-22.
Sanofi India has confirmed it will challenge the order through the appropriate appellate channels.

💡 Investors need not worry as the demand amount is immaterial compared to Sanofi India's overall financial scale. No immediate portfolio action is required.

Sanofi India to Host Investor Call on Feb 26 for FY2025 Audited Results

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 19 Feb 2026, 04:05 PM

Sanofi India Limited has scheduled an analyst and investor conference call on February 26, 2026, at 4:00 p.m. IST. The primary objective of the call is to discuss the audited financial results for the quarter and full year ended December 31, 2025. Investors are required to pre-register by 12:00 p.m. IST on the day of the call to participate in the Q&A session. The company will also provide a one-way audio webcast for those who wish to listen without participating in the discussion.

Investor call scheduled for February 26, 2026, between 4:00 p.m. and 5:00 p.m. IST
Focus on audited financial results for the quarter and year ended December 31, 2025
Pre-registration is mandatory and closes at 12:00 p.m. IST on February 26, 2026
Management will conduct a Q&A session in the order of participant registration
Universal dial-in numbers provided are +91 22 6280 1191 and +91 22 7115 8075

💡 Investors should register for the call to gain insights into the company's annual performance and future growth guidance. Monitor the management's commentary on product pipeline and margin sustainability during the Q&A.

Sanofi India Files Quarterly SEBI Compliance Certificate for Dec 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 05 Jan 2026, 03:55 PM

Sanofi India Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ended December 31, 2025. The certificate, issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited, confirms that dematerialization requests were processed within prescribed timelines. It verifies that physical security certificates were mutilated and cancelled after due verification and the register of members was updated. This is a standard procedural filing required for all listed companies to ensure the integrity of the shareholding process.

Compliance certificate submitted for the quarter ended December 31, 2025.
RTA MUFG Intime India confirms processing of dematerialization requests as per SEBI norms.
Physical certificates were mutilated and cancelled after verification by the depository participant.
Confirms that securities are listed on the stock exchanges where earlier securities were listed.

💡 This is a routine regulatory filing with no impact on the company's financial health or operations; no action is required from investors.

Sanofi India Receives ₹2.87 Crore GST Demand and Penalty Notice for FY 2018-23

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 30 Dec 2025, 04:17 PM

Sanofi India Limited has received an order from the CGST & Central Excise authorities in Mumbai for the period FY 2018-19 to FY 2022-23. The order demands a tax payment of ₹1.43 crore along with an equivalent penalty of ₹1.43 crore, totaling approximately ₹2.87 crore plus interest. The dispute pertains to the alleged wrong availment and utilization of Input Tax Credit (ITC). The company has stated its intention to appeal the order before higher tax authorities, suggesting no immediate financial outflow.

Tax demand of ₹1,43,49,690 issued for the period spanning FY 2018-19 to FY 2022-23.
A penalty of ₹1,43,49,690 has been imposed, matching the tax demand amount.
The total financial demand excluding interest is approximately ₹2.87 crore.
The order is based on allegations of incorrect availment and utilization of Input Tax Credit (ITC).
Sanofi India plans to contest the order by filing an appeal with higher tax authorities.

💡 The financial impact of this tax demand is immaterial relative to Sanofi India's overall revenue and profitability. Investors should treat this as a routine regulatory matter and focus on the company's core business performance.

Sanofi India Announces Trading Window Closure from Jan 1, 2026 for FY25 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Dec 2025, 01:12 PM

Sanofi India Limited has notified the stock exchanges regarding the closure of its trading window starting January 1, 2026. This measure is taken in compliance with SEBI Insider Trading regulations ahead of the declaration of financial results for the quarter and year ending December 31, 2025. The trading window will remain closed for all designated persons and their immediate relatives. It is scheduled to reopen 48 hours after the financial results are officially announced to the exchanges.

Trading window closure to commence from January 1, 2026.
Closure pertains to the financial results for the quarter and year ending December 31, 2025.
The window will remain closed until 48 hours after the results are disclosed to BSE and NSE.
Complies with SEBI (Prohibition of Insider Trading) Regulations, 2015.
Standard regulatory procedure for designated persons and insiders.

💡 This is a routine compliance filing and does not impact the company's fundamentals. Investors should monitor the upcoming earnings announcement for actual performance metrics.

Sanofi India Receives Tax Demand of Rs 24.10 Lakh from Gujarat State Tax Authority

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 24 Dec 2025, 02:06 PM

Sanofi India Limited has received a tax demand order from the Office of the Deputy Commissioner of State Tax, Ahmedabad, for the financial year 2018-19. The total demand amounts to Rs 24,10,359, which includes tax, interest, and penalties. The dispute arises from an alleged excess claim of Input Tax Credit (ITC) in GSTR-3B compared to GSTR-2A. The company has stated its intention to appeal this order before higher tax authorities.

Total demand of Rs 24,10,359 issued by the Deputy Commissioner of State Tax, Ahmedabad.
Demand breakdown includes Rs 12,95,930 in tax, Rs 9,84,836 in interest, and Rs 1,29,593 in penalty.
The order pertains to FY 2018-19 regarding discrepancies in Input Tax Credit (ITC) claims.
Sanofi India plans to contest the order by filing an appeal with higher tax authorities.

💡 No immediate action is required as the financial impact is immaterial relative to the company's overall operations. This appears to be a routine tax reconciliation matter.

Sanofi India Receives Tax Demand of Rs 14.29 Lakh for FY 2021-22

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 22 Dec 2025, 11:30 AM

Sanofi India Limited has received a tax demand order from the Department of Trade and Taxes, Delhi, for the financial year 2021-22. The total demand amounts to Rs 14,29,326, which includes a tax component of Rs 8,01,634, interest of Rs 5,47,528, and a penalty of Rs 80,164. The order was issued primarily due to the non-availability of vendor confirmations during the assessment process. The company has indicated that it will file an appeal against this order before the Higher Tax Authorities.

Total tax demand of Rs 14,29,326 issued by the Assistant Commissioner, Delhi.
Demand breakdown includes Rs 8.01 lakh in tax, Rs 5.47 lakh in interest, and Rs 0.80 lakh in penalty.
The order pertains to the financial year 2021-22 assessment.
The dispute arises from the non-availability of vendor confirmations.
Sanofi India plans to contest the demand through an appeal to Higher Tax Authorities.

💡 No action is required as the financial impact of Rs 14.29 lakh is negligible relative to the company's scale of operations. This is a routine regulatory matter that does not affect the company's fundamental value.

View All SANOFI Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The core business (Diabetes insulin, Cardiovascular, CNS, and Oral Anti-diabetes) grew 4% YTD September 2025 and 5% on a quarter-to-quarter basis. Partnership-led revenue grew 2% YTD and 5% quarter-to-quarter.

Geographic Revenue Split

Not disclosed in available documents; however, operations are primarily focused on the Indian market through Sanofi India Limited.

Profitability Margins

Operating margins were reported at approximately 28% for the current quarter, driven by optimization and efficiency measures.

EBITDA Margin

Operating margins of 28% reflect core profitability; the company is actively pursuing optimization to enhance these levels further from the current 28% baseline.

⚙️ Operational Drivers

Key Suppliers

Emcure Pharmaceuticals is a key strategic partner for the distribution and potentially the supply chain of oral anti-diabetes products.

Manufacturing Efficiency

AI-driven forecasting has reached an accuracy level of +/- 1% compared to reality, significantly improving supply chain planning and reducing waste.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth is driven by a 'pivotal transformation' in 2025 involving strategic partnerships like the one with Emcure for oral anti-diabetes. The company is also focusing on new product launches such as Soliqua and expanding the 'share of voice' for glargine products (Lantus and Toujeo). Cost optimization, including a reduction in personnel costs from INR 56 Cr to INR 42 Cr (a 25% decrease) via VRS, is intended to protect margins.

Products & Services

Insulin cartridges, DispoPens, oral anti-diabetes medications, cardiovascular drugs, and CNS (Central Nervous System) therapies.

Brand Portfolio

Lantus, Toujeo, Soliqua.

New Products/Services

Launch of Soliqua and assessment of Type 1 Diabetes (T1D) innovations for the Indian market.

Market Expansion

Targeting the human insulin cartridges and DispoPen market, which has an estimated size of INR 450 Cr to INR 500 Cr, following the exit of a major competitor (Novo Nordisk).

Strategic Alliances

Partnership with Emcure Pharmaceuticals for the oral anti-diabetes segment announced in July 2025.

🌍 External Factors

Industry Trends

The industry is shifting toward biosimilars to improve the 'share of voice' for glargine in the marketplace. Sanofi is positioning itself by innovating in the T1D segment and adopting AI for operational forecasting and regulatory affairs.

Competitive Landscape

Key dynamics include the exit of Novo Nordisk from the human insulin cartridge and DispoPen market, creating a significant vacuum for Sanofi to fill.

Competitive Moat

The company maintains a strong competitive position in the insulin market (Lantus/Toujeo) and is capitalizing on competitor exits in the human insulin cartridge segment (INR 450-500 Cr market size). Sustainability is bolstered by a global commitment to net-zero emissions by 2045.

Macro Economic Sensitivity

Sensitive to changes in the regulatory environment and geopolitical stability which can impact the timeline for achieving corporate goals.

Consumer Behavior

Increased demand for advanced insulin delivery systems like cartridges and pens over traditional methods.

Geopolitical Risks

Geopolitical stability is cited as a significant uncertainty that could prevent the company from achieving its specified metrics or targets.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to complex regulatory requirements and health and safety standards; 100% of plants and offices are assessed for compliance.

Environmental Compliance

Committed to 100% renewable electricity by 2030 and zero landfill status as part of environmental responsibility initiatives.

⚠️ Risk Analysis

Key Uncertainties

Significant uncertainties inherent in forward-looking statements regarding the achievement of goals within specified timeframes due to regulatory and cost fluctuations.